-
In order to expand the pipeline, a large number of pharmaceutical companies are spending huge sums of money to initiate acquisitions
Time of Update: 2022-05-09
The acquisition, with a total value of approximately EUR 500 million (including milestone payments), will create significant synergies in terms of product portfolio and market coverage, providing multi-faceted neurointerventions for patients in key markets such as China, the United States, Europe and Japan Technologies and Solutions .
-
Pharmaceutical distribution companies released a quarterly report, and many net profits increased significantly
Time of Update: 2022-05-09
53%; Jiangzhong Pharmaceutical achieved an operating income of 931 million yuan, a year-on-year increase of 37.
41%; China Resources Boya Bio achieved a total operating income of about 655 million yuan, a year-on-year increase of 4.
-
The revenue of 44 pharmaceutical companies exceeded 10 billion yuan, and the gross profit margin of 3 companies including Changchun Hi-Tech and Hengrui increased by over 80% year-on-year
Time of Update: 2022-05-09
Judging from the three pharmaceutical companies with a gross profit margin of over 80%, Changchun Hi-Tech will achieve a net profit of 610 million yuan in 2021, a year-on-year decrease of 22.
-
Financing in the global biotechnology field is still hot, and two Chinese companies are "loved" by capital
Time of Update: 2022-05-09
In the Series C financing of up to US$720 million, including Temasek, Invesco Development Market Fund, Zhenggu Capital, GL Ventures, Yunfeng Capital, Eli Lilly Asia Ventures, Boyu Capital, Qiming Venture Partners, Highlight Capital and other large investments Institutions are on the list of participating investment, which shows that these institutions are optimistic about the company .
-
A group of pharmaceutical company executives have dropped their salaries!
Time of Update: 2022-05-09
[Pharmaceutical Network Industry News] Recently, the proxy statement signed by Regeneron shareholders in 2022 shows that its chief executive officer (CEO) Leonard S.
At present, in addition to the salary cuts of Regeneron’s CEO and chief scientific officer, according to the author, many corporate executives have also received salary cuts .
-
The painkiller market has promising prospects, and domestic pharmaceutical companies are making efforts
Time of Update: 2022-05-09
On February 10, Kangfang Bio announced that the clinical trial application for the innovative nerve growth factor (NGF) monoclonal antibody injection independently developed by the company has been approved by the Center for Drug Evaluation (CDE) of the State Drug Administration.
-
Pharmaceutical companies actively participate in the consistency evaluation of generic drugs, and another company has been reviewed in May
Time of Update: 2022-05-08
Lisheng Pharmaceutical announced at noon on May 5 that recently, the company received the "Approval Notice of Drug Supplementary Application" for Donepezil Hydrochloride Tablets 5mg issued by the State Drug Administration, and the drug passed the consistency evaluation of the quality and efficacy of generic drugs.
-
Another large number of medical consumables will usher in a wave of price cuts!
Time of Update: 2022-05-08
[Pharmaceutical Network Industry News] In recent years, with the continuous advancement of pharmaceutical reform, the centralized procurement of drugs and medical consumables has gradually become a normal trend, which is further guiding the artificially high prices to return to a reasonable level, reducing the burden of patients' medical expenses, and purifying medicines.
-
In the first half of 2022, more than 120 senior executives of pharmaceutical companies have changed, including many chairman of the board
Time of Update: 2022-05-08
Heavy Pharmaceutical Holdings On March 11, Heavy Pharmaceutical Holdings announced that due to personal reasons, Liu Shaoyun applied to resign from the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors .
-
The pharmaceutical equipment industry still maintained a growth trend in the first quarter, and many companies achieved a "good start"
Time of Update: 2022-05-08
Pharmaceutical machine companies need to combine industry needs to create high-performance, high-reliability Unique equipment can help enterprises to produce high-quality and stable production, thereby reducing costs .
-
Nearly 300 pharmaceutical companies distributed cash dividends of 16 over 100 million yuan
Time of Update: 2022-05-08
, including Zhendong Pharmaceutical, Yunnan Baiyao, Daan Gene, WuXi AppTec, The amount of cash dividends such as Fosun Pharma has exceeded 1 billion yuan .
Specifically, Zhendong Pharmaceutical plans to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares based on the total share capital of 1.
-
In April, the "steering wheel" of institutional research turned around, and these pharmaceutical stocks are still popular among institutions
Time of Update: 2022-05-08
In the first quarter of 2022, the company's performance continued to grow, with an operating income of 431 million yuan, a year-on-year increase of 66.
49% year-on-year, and the net profit after deducting non-returning to the parent company increased by 15.
-
How are multinational pharmaceutical companies performing in the Chinese market?
Time of Update: 2022-05-08
Novartis' sales revenue in the Chinese market in 2021 will increase by 18% year-on-year to US$3.
According to the 2021 annual report released by Merck, the company's revenue in 2021 will increase by 17% year-on-year to $48.
Among them, Merck China's total revenue increased by 60% year-on-year to US$4.
-
With the continuous efforts of local pharmaceutical companies, there is continuous good news in the hypoglycemic drug market
Time of Update: 2022-05-08
Data shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
-
Enterprise chapter of major pharmaceutical events in April: a large number of pharmaceutical companies have met, repurchased shares, and resigned
Time of Update: 2022-05-08
The author sorted out and found that a large number of pharmaceutical companies have held meetings, repurchased shares, and resigned, which are worth reviewing .
924 million yuan to repurchase company shares Tigermed announced at the end of April that on April 28, 2022, the company spent about RMB39.
-
In April, no less than 30 pharmaceutical companies released their first-quarter reports, and the performance of a pharmaceutical company soared nearly 7 times.
Time of Update: 2022-05-08
Among them, there were 2 companies whose net profit increased by more than 100%, namely Shanghai Yizhong and Wantai Bio .
Wantai Bio's 2022 quarterly report data shows that in the first quarter of 2022, the company's operating income increased by 284.
-
The 8 major forums of the expert lecture hall of the 2022 Qingdao International Water Conference will start online in May!
Time of Update: 2022-05-08
The knowledge of this online lecture covers seawater desalination, industrial water saving and sewage recycling, urban water affairs development, water environment governance and water ecological restoration, water purification, green and low-carbon coordinated development and other sectors.
-
The pace of approval and marketing of domestic innovative drugs will continue to accelerate, bursting out more new vitality
Time of Update: 2022-05-08
The industry predicts that 19 blockbuster new drugs will be approved in 2022, and two of the 19 innovative drugs will be independently developed by domestic pharmaceutical companies .
-
Notice on "The 88th API China is postponed to August 3-5"
Time of Update: 2022-05-08
Dear exhibitors, visitors and friends in the industry: Thank you for your attention and support to the "China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (hereinafter referred to as API China)!
-
The entry of multinational pharmaceutical companies into the traditional Chinese medicine market may further promote the modernization of the industry
Time of Update: 2022-05-08
Analysts said that in recent years, China's support for traditional Chinese medicine has continued to increase, and the traditional Chinese medicine market has great potential, which is attractive to multinational pharmaceutical companies to a certain extent .
